Presentations & Publications

Publications

March 07, 2026 | Future Oncology

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib

Dec 7-10, 2024 | ASH 2024

POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Pankit Vachhani

Dec 7-10, 2024 | ASH 2024

Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed Refractory Myelofibrosis

John O. Mascarenhas

Dec 7-10, 2024 | ASH 2024

Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis

John O. Mascarenhas

June 8-11, 2023 | EHA 2023

Adding Navtemadlin to Ruxolitinib Potentiates Apoptosis in Myeloblasts From Patients With Myelofibrosis

Tracy Clevenger